Setsuko Chambers
Experienced in Chronic Familial Neutropenia

Dr. Setsuko Chambers

Oncology
Banner Health
University Of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Experienced in Chronic Familial Neutropenia
Banner Health
University Of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

My research interests include: CSF-1 and its role in neoplastic progression and metastasis of ovarian cancer; the role of RNA binding proteins and miRNAs in regulation of CSF-1 expression. Androgens and neoplastic transformation of normal ovarian surface epithelium. and the c-fms proto-oncogene and breast cancer invasiveness and bone metastasis; mechanism of regulation of c-fms expression novel c-fms RNA binding proteins and miRNAs.

Dr. Chambers is rated as an Experienced provider by MediFind in the treatment of Chronic Familial Neutropenia. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Oophorectomy.

Her clinical research consists of co-authoring 54 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Brown University Program In Medicine, 1980
Residency
Yale New Haven Hospital, Obstetrics & Gynecology, 1984
Specialties
Oncology
Licenses
Obstetrics & Gynecology in AZ
Board Certifications
American Board Of Obstetrics & Gynecology
American Board Of Obstetrics & Gynecology-Gynecologic Oncology
Fellowships
Yale University School Of Medicine, Gynecologic Oncology, 1986
Hospital Affiliations
Banner - University Medical Center Tucson
Banner - University Medical Center South
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

University of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, Tucson, AZ 85719
Call: 520-694-2873

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: November 13, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine, Poly ICLC
Study Phase: Phase 1/Phase 2
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Enrollment Status: Completed
Publish Date: May 17, 2023
Intervention Type: Drug
Study Drugs: Carboplatin/Paclitaxel, Trastuzumab
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Procedure, Device, Drug
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 12 Less Clinical Trials

56 Total Publications

miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.
miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.
Journal: Scientific reports
Published: May 19, 2024
View All 56 Publications
Similar Doctors
Advanced in Chronic Familial Neutropenia
Dr. Delmer A. Montoya-Motino
Oncology | Hematology
Advanced in Chronic Familial Neutropenia
Dr. Delmer A. Montoya-Motino
Oncology | Hematology

Tmc Medical Network

603 N Wilmot Rd, Suite 151, 
Tucson, AZ 
 (0.1 miles away)
520-420-2560
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Delmer Montoya-Motino is an Oncologist and a Hematologist in Tucson, Arizona. Dr. Montoya-Motino is rated as an Advanced provider by MediFind in the treatment of Chronic Familial Neutropenia. His top areas of expertise are Idiopathic Neutropenia, Chronic Familial Neutropenia, Agranulocytosis, and Triple-Negative Breast Cancer. Dr. Montoya-Motino is currently accepting new patients.

Distinguished in Chronic Familial Neutropenia
Dr. Laurie L. Chen
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic Familial Neutropenia
Dr. Laurie L. Chen
Hematology Oncology | Hematology | Oncology

Tmc Medical Network

5301 E Grant Rd, 
Tucson, AZ 
 (2.2 miles away)
520-324-4230
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Laurie Chen is a Hematologist Oncology specialist and a Hematologist in Tucson, Arizona. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Chronic Familial Neutropenia. Her top areas of expertise are Pleuropulmonary Blastoma, Hemochromatosis, Chronic Familial Neutropenia, and Agranulocytosis. Dr. Chen is currently accepting new patients.

Rachel Swart
Advanced in Chronic Familial Neutropenia
Dr. Rachel Swart
Oncology
Advanced in Chronic Familial Neutropenia
Dr. Rachel Swart
Oncology

University Of Arizona Cancer Center

1891 West Orange Grove Road, Building 1, 
Tucson, AZ 
 (10.7 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy traveling and cycling. Dr. Swart is rated as a Distinguished provider by MediFind in the treatment of Chronic Familial Neutropenia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, and Angiosarcoma.

VIEW MORE CHRONIC FAMILIAL NEUTROPENIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chambers's expertise for a condition
ConditionClose
  • Elite
  • Ovarian Cancer
    Dr. Chambers is
    Elite
    . Learn about Ovarian Cancer.
    See more Ovarian Cancer experts
  • Distinguished
  • Endometrial Cancer
    Dr. Chambers is
    Distinguished
    . Learn about Endometrial Cancer.
    See more Endometrial Cancer experts
  • Malignant Mixed Mullerian Tumor
    Dr. Chambers is
    Distinguished
    . Learn about Malignant Mixed Mullerian Tumor.
    See more Malignant Mixed Mullerian Tumor experts
  • Ovarian Carcinosarcoma
    Dr. Chambers is
    Distinguished
    . Learn about Ovarian Carcinosarcoma.
    See more Ovarian Carcinosarcoma experts
  • Sertoli-Leydig Cell Tumor
    Dr. Chambers is
    Distinguished
    . Learn about Sertoli-Leydig Cell Tumor.
    See more Sertoli-Leydig Cell Tumor experts
  • Testicular Yolk Sac Tumor
    Dr. Chambers is
    Distinguished
    . Learn about Testicular Yolk Sac Tumor.
    See more Testicular Yolk Sac Tumor experts
  • Virilizing Ovarian Tumor
    Dr. Chambers is
    Distinguished
    . Learn about Virilizing Ovarian Tumor.
    See more Virilizing Ovarian Tumor experts
  • Advanced
  • BRCA Positive Breast Cancer
    Dr. Chambers is
    Advanced
    . Learn about BRCA Positive Breast Cancer.
    See more BRCA Positive Breast Cancer experts
  • Desmoplastic Small Round Cell Tumor
    Dr. Chambers is
    Advanced
    . Learn about Desmoplastic Small Round Cell Tumor.
    See more Desmoplastic Small Round Cell Tumor experts
  • Endometrial Stromal Sarcoma
    Dr. Chambers is
    Advanced
    . Learn about Endometrial Stromal Sarcoma.
    See more Endometrial Stromal Sarcoma experts
  • HER2 Negative Breast Cancer
    Dr. Chambers is
    Advanced
    . Learn about HER2 Negative Breast Cancer.
    See more HER2 Negative Breast Cancer experts
  • Li-Fraumeni Syndrome
    Dr. Chambers is
    Advanced
    . Learn about Li-Fraumeni Syndrome.
    See more Li-Fraumeni Syndrome experts
  • Oophorectomy
    Dr. Chambers is
    Advanced
    . Learn about Oophorectomy.
    See more Oophorectomy experts
View All 9 Advanced Conditions
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Chambers is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Chambers is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Bladder Reconstruction
    Dr. Chambers is
    Experienced
    . Learn about Bladder Reconstruction.
    See more Bladder Reconstruction experts
  • Breast Cancer
    Dr. Chambers is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Cervical Cancer
    Dr. Chambers is
    Experienced
    . Learn about Cervical Cancer.
    See more Cervical Cancer experts
  • Chronic Familial Neutropenia
    Dr. Chambers is
    Experienced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.